UI Hospitals and Clinics

Clinical Trial Details

Short Title
Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Official Title

A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus


Participants in this study have uterine cancer that has re-grown or has not responded to prior treatment. The purpose of this study is to find out if the study drug, Ixabepilone, works in treating this type of cancer and to find out what side effects are caused by treatment with this drug. In addition to the treatment part of this study, the researchers plan to test samples of the tumor (if available from a previous surgery).  The purpose of this research is to determine if this testing can be used in the future to determine ahead of time which patients may respond to treatment or have good prognosis. Approximately 10 people will take part in this study conducted by investigators at the University of Iowa. Participation in this study will last as long as there is evidence that the tumor is not growing and there are no serious side effects.

Start Date
May 25, 2011
End Date
May 25, 2021
Gender Preference
Age Group
18 - 99 years
Principal Investigator
David Bender, MD
Contact Info

Sharon Stockman, (319) 356-2015

Obstetrics/ Gynecology
201104768 ; Bender ; cancer ; Carcinosarcoma ; Carcinosarcoma in uterus ; Phase two ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.